Dr. Giralt on Current Standard of Care for Newly Diagnosed Multiple Myeloma

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses the current frontline standard of care for patients with multiple myeloma.

The current frontline standard of care in multiple myeloma is bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd), explains Giralt. In patients with renal failure or dysfunction, the combination of lenalidomide, cyclophosphamide, and dexamethasone is also commonly used, according to Giralt.

Randomized trials have shown that 3-drug regimens are better than 2-drug regimens for both transplant-eligible and -ineligible patients. The SWOG S0777 trial showed that VRd had an improved survival compared with lenalidomide and dexamethasone alone, concludes Giralt.